RetiredCapital BluecrossPolicy MP 1.146

Vagus Nerve Blocking Therapy for the Treatment of Obesity

Customize your policy alerts

Sign up for Capital Bluecross Policy MP 1.146 alerts

Get alerted when Policy MP 1.146 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs Capital Blue Cross's stance on intra-abdominal vagus nerve blocking therapy (implantable device therapy) for treatment of obesity and applies to applicable Capital Blue Cross products and programs.

Policy Summary

PayerCapital Bluecross

PolicyVagus Nerve Blocking Therapy for the Treatment of Obesity

Policy CodePolicy MP 1.146

Change TypeRetirement

Effective DateRETIRED 5/1/2026

Last ReviewNov 24, 2025

Next Review DateN/A

Key ActionVerify member benefits and obtain any required prior authorization before proceeding, since the therapy is investigational and coverage varies by product.

SourceLink

POLICY UPDATE CHANGES

Retirement recorded — policy retired (see policy history entries).

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

RetiredCapital BluecrossPolicy MP 1.146

Vagus Nerve Blocking Therapy for the Treatment of Obesity

Customize your policy alerts

Sign up for Capital Bluecross Policy MP 1.146 alerts

Get alerted when Policy MP 1.146 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerCapital Bluecross

PolicyVagus Nerve Blocking Therapy for the Treatment of Obesity

Policy CodePolicy MP 1.146

Change TypeRetirement

Effective DateRETIRED 5/1/2026

Last ReviewNov 24, 2025

Next Review DateN/A

Key ActionVerify member benefits and obtain any required prior authorization before proceeding, since the therapy is investigational and coverage varies by product.

SourceLink

POLICY UPDATE CHANGES

Retirement recorded — policy retired (see policy history entries).

FDA PMA notedRegulatory

Not marketed (2018)Commercial availability

64999 investigationalCoding

RetiredPolicy status

Coverage Criteria and Policy Statement

Not medically necessary / Investigational

Covered when ALL of the following are met:

Investigational stance: Intra-abdominal vagus nerve blocking therapy is considered investigational in all situations for treatment of obesity; evidence is insufficient to determine effects on health outcomes.

Includes devices such as the Maestro system despite FDA PMA; randomized sham-controlled trials did not meet primary efficacy thresholds and longer-term analyses have limitations.

The existence of this medical policy does not mean the service is a covered benefit under a member's health benefit plan. Benefit determinations are based on the applicable health benefit plan language, and medical policies do not constitute a description of benefits. Providers and members should consult the member's health benefit plan or contact Capital Blue Cross for specific benefit information.

This policy includes a Retirement entry dated 11/24/2025 in the policy history. The retirement notation indicates the policy is no longer active after that administrative date and may affect future coverage determinations; providers should verify current policy status and applicable plan provisions when submitting claims or seeking prior authorization.

Intra-abdominal vagus nerve blocking therapy is designated investigational in all situations because the body of evidence is insufficient to demonstrate meaningful health benefit. Randomized sham-controlled trials did not meet the prespecified primary efficacy threshold (a ≥10% difference in the primary outcome at 12 months), and longer-term and post hoc analyses have limitations such as missing data and unblinding. On this basis, the policy concludes that evidence is inadequate to determine the therapy's effects on health outcomes.

Coding and Regulatory Information

Investigational; therefore, not coveredCPTNot Covered

64999

Unlisted procedure, nervous system

Policy-coded proceduresCPT

64999

Unlisted procedure, nervous system (added to policy coding list)

FDA device labeling BMI eligibility criteria (age and BMI thresholds)

Age eligibilityAdults age 18 years and older

BMI eligibility — class III obesityBMI 40 to 45 kg/m2

BMI eligibility — class II with comorbidityBMI 35 to 39.9 kg/m2 with 1 or more obesity-related conditions (e.g., hypertension, hypercholesterolemia)

Prior treatment requirementFailed at least 1 supervised weight management program within the past 5 years

Imaging incompatibility noteImplantable components are incompatible with magnetic resonance imaging (MRI)

Provider Requirements and Billing Guidance

Prior Authorization

Verify member benefits and PA due to investigational status

Because intra‑abdominal vagus nerve blocking therapy is designated investigational and benefits vary by product, verify the member’s benefits and obtain any required prior authorization from the member’s plan before proceeding.

Confirm whether the member’s health benefit plan covers investigational services for vagus nerve blocking therapy.
Contact Capital Blue Cross or consult the member’s plan documents for benefit and prior authorization requirements.

Prior Authorization

Obtain prior authorization and use current procedure codes

Prior authorization may be required for vagus nerve blocking procedures; verify PA requirements and use current codes (including code 64999 where applicable) when requesting authorization from the member’s plan.

Confirm prior authorization rules with the member’s plan administrator before scheduling or billing the procedure.
When requesting authorization, reference the current policy coding list and policy history to ensure correct codes are used.

Background and Clinical Context

Vagus nerve blocking therapy (vagal nerve blockade, e.g., the Maestro system) uses an implanted neuroblocking pulse generator with leads placed on the intra-abdominal vagal trunks to intermittently block vagal signals with the goal of reducing hunger and promoting satiety. Although the Maestro Rechargeable System received FDA premarket approval in 2015 for selected adults meeting device labeling BMI criteria, randomized sham-controlled trials (EMPOWER and ReCharge) failed to meet the trials' prespecified primary efficacy thresholds, and subsequent longer-term analyses have methodologic limitations. For these reasons, the therapy is considered investigational and not supported as a standard treatment option for obesity.

Definitions and Device Information

Maestro Rechargeable System — device description and FDA PMA status

Device descriptionAn implantable neuroblocking pulse generator with leads placed on intra-abdominal vagal trunks that delivers intermittent electrical stimulation to block vagal signals and reduce hunger/induce satiety

FDA approval (PMA)Maestro Rechargeable System approved by FDA January 2015 via the premarket approval (PMA P130019)

Commercial availabilityCommercial availability unclear; FDA noted Maestro Rechargeable System described as 'no longer marketed as of September 2018' on its Weight-Loss and Weight-Management Devices webpage

FDA product code and safety notesFDA product code: PIM; implantable components incompatible with MRI; post-approval updates to device firmware and follow-up study protocol documented in PMA database

Terminology for vagal nerve blocking therapy (vBloc/Maestro)

Policy Summary

PayerCapital Bluecross

PolicyVagus Nerve Blocking Therapy for the Treatment of Obesity

Policy CodePolicy MP 1.146

Change TypeRetirement

Effective DateRETIRED 5/1/2026

Last ReviewNov 24, 2025

Next Review DateN/A

Key ActionVerify member benefits and obtain any required prior authorization before proceeding, since the therapy is investigational and coverage varies by product.

SourceLink

On This Page

Documentation Required

Document failed conservative therapy and bariatric surgery context

Document prior conservative management and any bariatric surgery context in the medical record; the policy notes bariatric surgery and conservative treatments as established options and failed conservative therapy is relevant to clinical context even though vagus nerve blocking is investigational.

Record attempts and outcomes of supervised weight‑management programs and other conservative measures.
Note if the patient is a candidate for or has undergone bariatric surgery, and document rationale for considering alternative therapies.

Note

Follow policy product‑variation and administrative guidance

Providers should follow the policy notes and procedural guidance included in the document when preparing submissions; consult the policy text and history for any provider-specific instructions or administrative updates.

Refer to the policy’s product variation and administrative sections for program‑specific applicability.
Check the policy history for administrative updates that may affect submission or authorization processes.

Note

Verify member plan benefits for reimbursement

Benefit determinations depend on the member’s specific health benefit plan language; the existence of this medical policy does not guarantee coverage or reimbursement under a given plan.

Verify whether the member’s contract includes coverage for investigational services or specific exclusions.
Contact Capital Blue Cross for benefit confirmation when plan language is unclear.

Documentation Required

Document coding changes and reference policy history on claims

Maintain documentation of coding changes and reference the policy history when submitting claims to ensure use of current, supported codes.

Include policy version/date and coding list copy with claims when relevant.
Retain records showing which codes were in effect at the time of service.

Denial Risk

Investigational status may lead to claim denial

Because the policy states intra‑abdominal vagus nerve blocking therapy is investigational in all situations, claims for this therapy may be denied on the basis of investigational status.

Do not assume coverage; obtain benefit confirmation before performing or billing the procedure.
Be prepared for claim denial and document clinical rationale if proceeding despite likely noncoverage.

Billing Rule

Coding-based denial risk for CPT 64999

Procedure code 64999 (unlisted procedure, nervous system) is listed in the policy’s investigational/noncovered coding table; billing this code for vagus nerve blocking therapy is linked to noncoverage and may trigger denials.

When submitting claims, ensure use of the most current code list and provide supporting documentation if using unlisted codes.
Anticipate denials if 64999 is used for services the policy designates investigational.

Denial Risk

Coding changes in policy history can trigger denials

Policy history documents deletions and later additions to the coding list (deleted codes effective 01/01/23 and added code 64999 in 11/03/2023); unsupported, deleted, or changed codes may trigger claim denials if billed inconsistently with the policy history.

Review the policy history for effective dates of code changes before billing.
Provide documentation that the code billed was valid and supported at the time of service to reduce denial risk.

vagal nerve blocking therapy (also referred to as vagal nerve blockade, vBloc, or Maestro)

Common trade nameMaestro Rechargeable System (vBloc) — EnteroMedics / ReShape Lifesciences

Anatomic targetBranches of the vagus nerve on the anterior abdominal wall (intra-abdominal vagal trunks)

Therapy descriptionIntermittent electrical stimulation via an implanted pulse generator and abdominal leads to disrupt hunger signals and promote satiety